Potential pathological advantages of En Bloc-resection of non-muscle invasive bladder tumours – a multinational randomised trial

TY - ABST

T1 - Potential pathological advantages of En Bloc-resection of non-muscle invasive bladder tumours – a multinational randomised trial

AU - Nielsen, Ninna Kjær

PY - 2025

Y1 - 2025

N2 - Introduction: En Bloc-resection (EBR) of non-muscle invasive bladder cancer (NMIBC) can potentially overcome some of the drawbacks of conventional transurethral resection of bladder tumours (cTURB), particularly regarding the pathological quality of the specimen. The aim of this study is to evaluate the pathological advantages of EBR compared with cTURB of NMIBC in terms of correct staging and grading. Method: In this multinational randomised controlled trial, patients with suspected NMIBC tumours measuring 1-4 cm were randomised to either EBR or cTURB. A central pathology revision will be performed of all specimens, and the primary endpoint is the proportion of patients with unaltered T-stage following pathology revision compared with the initial pathology assessment. All results are analysed as intention to treat. Results: As of March 2025, 96 specimens have been revised. 45 patients were randomised to EBR, 51 patients to cTURB. In the EBR group, 34 patients (76%, 95% CI: 60–87) had unaltered T-stage, compared to 40 patients (78%, 95% CI: 64–88) in the cTURB group (p = 0.70). The number of patients with unaltered malignancy grade was 34 (76%, 95% CI: 60–87) in the EBR group and 37 (73%, 95% CI: 58–84) in the cTURB group (p = 0.70). Conclusion: In the preliminary data, we were not able to confirm our hypothesis that more patients in the EBR group would have unaltered T-stage and grade at revision compared to the cTURB group. We expect to present the complete dataset and analyses at NUF 2025.

AB - Introduction: En Bloc-resection (EBR) of non-muscle invasive bladder cancer (NMIBC) can potentially overcome some of the drawbacks of conventional transurethral resection of bladder tumours (cTURB), particularly regarding the pathological quality of the specimen. The aim of this study is to evaluate the pathological advantages of EBR compared with cTURB of NMIBC in terms of correct staging and grading. Method: In this multinational randomised controlled trial, patients with suspected NMIBC tumours measuring 1-4 cm were randomised to either EBR or cTURB. A central pathology revision will be performed of all specimens, and the primary endpoint is the proportion of patients with unaltered T-stage following pathology revision compared with the initial pathology assessment. All results are analysed as intention to treat. Results: As of March 2025, 96 specimens have been revised. 45 patients were randomised to EBR, 51 patients to cTURB. In the EBR group, 34 patients (76%, 95% CI: 60–87) had unaltered T-stage, compared to 40 patients (78%, 95% CI: 64–88) in the cTURB group (p = 0.70). The number of patients with unaltered malignancy grade was 34 (76%, 95% CI: 60–87) in the EBR group and 37 (73%, 95% CI: 58–84) in the cTURB group (p = 0.70). Conclusion: In the preliminary data, we were not able to confirm our hypothesis that more patients in the EBR group would have unaltered T-stage and grade at revision compared to the cTURB group. We expect to present the complete dataset and analyses at NUF 2025.

M3 - Konferenceabstrakt til konference

T2 - 35th Congress of the Scandinavian Association of Urology (NUF)

Y2 - 4 June 2025 through 7 June 2025

ER -